Lead sponsor
Novartis
17 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
17
Trials led
0
Ongoing
4,089
Total enrollment
268
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
4
Phase 3
6
Phase 4
7
Trials by status
Completed
16
Terminated
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's DiseaseAge 50-85Ph 3Completed868
Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)Parkinson's disease dementiaPh 3Completed583
Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's DiseaseAlzheimer's diseasePh 3Completed262
Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor TreatmentAlzheimer's diseasePh 4Completed204
Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's DiseaseAlzheimer's diseasePh 4Completed150
Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Diseasemild-to-moderate ADPh 4Completed80
Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's PatientsAlzheimer's diseasePh 2Completed31
Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.Alzheimer's diseasePh 2Completed27
To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients-Ph 2Completed24
Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive ImpairmentMMSE 23-27Ph 3Terminated24
To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's PatientsAge 40-85Ph 2Completed21
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)CDR global 0.5Ph 3Completednot disclosed